← Leaderboards
Renata Pasqualini
Rutgers Biomedical And Health Sciences
$15,543,620
Attributed
$24,691,077
Total exposure
23
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,691,077 · 23
By mechanism
R01$15,008,711 · 11
U01$5,310,776 · 2
R21$1,671,648 · 4
P50$1,513,123 · 2
R33$1,018,211 · 1
R03$168,608 · 1
Top collaborators
- Wadih Arap26 shared
- Steven K. Libutti10 shared
- C Jeffrey Brinker5 shared
- Vittorio Cristini5 shared
- Reynold Alexander Panettieri5 shared
- Dimitrios P Kontoyiannis2 shared
- Utz Herbig1 shared
- Joachim B. Kohn1 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Wadih Arap$12,814,372
- Steven K. Libutti$7,794,095
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseDesignIn VivoLigandsPeptidesTumorAngiogenesisPhage DisplayMalignant NeoplasmsReceptorCellsBacteriophagesImageIn VitroMediatingMolecularGene ExpressionInsightLeadNeoplastic CellHomingBlood VesselsVascular EndotheliumTechnology
Grant awards (84)
Identification of Molecular Features Associated with Vascular Alterations in Aging$431,750
R21 · FY2025 · AG · contact PI
Ligand-directed therapeutic CRISPR/Cas gene editing in tumor cells$183,494
R21 · FY2025 · CA · contact PI
Phage-based therapeutic gene delivery targeting multiple compartments in solid tumors$403,686
R21 · FY2024 · CA · contact PI
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$341,181
R01 · FY2024 · CA · contact PI
Ligand-directed therapeutic CRISPR/Cas gene editing in tumor cells$220,193
R21 · FY2024 · CA · contact PI
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$351,955
R01 · FY2023 · CA · contact PI
Rutgers Optimizes Innovation (ROI) Program$999,999
U01 · FY2022 · HL
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$629,467
R01 · FY2022 · CA · contact PI
Functional Targeting of the Tyrosine Kinase EphA5 in Radiation-resistant Lung Cancer$356,438
R01 · FY2022 · CA · contact PI
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$351,955
R01 · FY2022 · CA · contact PI
Rutgers Optimizes Innovation (ROI) Program$999,999
U01 · FY2021 · HL
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,358
R01 · FY2021 · CA · contact PI
Rutgers Optimizes Innovation (ROI) Program$443,600
U01 · FY2021 · HL
Targeting Lymphatic Vessels for Ligand Directed Imaging$363,713
R01 · FY2021 · CA · contact PI
Functional Targeting of the Tyrosine Kinase EphA5 in Radiation-resistant Lung Cancer$363,713
R01 · FY2021 · CA · contact PI
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$358,185
R01 · FY2021 · CA · contact PI
Rutgers Optimizes Innovation (ROI) Program$999,999
U01 · FY2020 · HL
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,804
R01 · FY2020 · CA · contact PI
Functional Targeting of the Tyrosine Kinase EphA5 in Radiation-resistant Lung Cancer$363,713
R01 · FY2020 · CA · contact PI
Targeting Lymphatic Vessels for Ligand Directed Imaging$363,713
R01 · FY2020 · CA · contact PI
Designing a transcriptome-based, targeted theranostic platform for prostate cancer$356,850
R01 · FY2020 · CA · contact PI
Rutgers Optimizes Innovation (ROI) Program$999,999
U01 · FY2019 · HL
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$623,916
R01 · FY2019 · CA · contact PI
Targeting Lymphatic Vessels for Ligand Directed Imaging$352,801
R01 · FY2019 · CA · contact PI
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$673,092
R01 · FY2018 · CA · contact PI
Targeting Lymphatic Vessels for Ligand Directed Imaging$327,341
R01 · FY2018 · CA · contact PI
Targeting Lymphatic Vessels for Ligand Directed Imaging$34,656
R01 · FY2018 · CA · contact PI
Targeting Lymphatic Vessels for Ligand Directed Imaging$346,556
R01 · FY2017 · CA · contact PI
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc$366,250
R01 · FY2014 · HL
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc$355,786
R01 · FY2013 · HL
Ligand-Directed Targeting in Prostate Cancer Metastasis$229,889
P50 · FY2013 · CA · contact PI
Ligand-Directed Targeting in Prostate Cancer Metastasis$253,102
P50 · FY2012 · CA · contact PI
Targeted Modulation of Angiogenesis by VEGFR Peptidomimetic Antagonists$230,000
R01 · FY2012 · EY · contact PI
Targeted Modulation of Angiogenesis by VEGFR Peptidomimetic Antagonists$143,507
R01 · FY2012 · EY · contact PI
High-throughput Screenings to Identify Host Receptors for Staphylococcal Adhesins$84,304
R03 · FY2012 · AI · contact PI
Targeted Modulation of Angiogenesis by VEGFR Peptidomimetic Antagonists$373,507
R01 · FY2011 · EY · contact PI
Ligand-Directed Tumor Targeting in Preclinical Models$283,822
R01 · FY2011 · CA · contact PI
Ligand-Directed Targeting in Prostate Cancer Metastasis$243,762
P50 · FY2011 · CA · contact PI
Novel Clinical Diagnostic Targets For Detection of Invasive Mold Aspergillosis$195,525
R21 · FY2011 · AI
High-throughput Screenings to Identify Host Receptors for Staphylococcal Adhesins$84,304
R03 · FY2011 · AI · contact PI
Targeted Modulation of Angiogenesis by VEGFR Peptidomimetic Antagonists$389,070
R01 · FY2010 · EY · contact PI
Integration of Vascular Genomics and Proteomics for Diagnosis and Therapy of Canc$340,482
R33 · FY2010 · CA · contact PI
Ligand-Directed Tumor Targeting in Preclinical Models$292,600
R01 · FY2010 · CA · contact PI
Ligand-Directed Targeting in Prostate Cancer Metastasis$247,258
P50 · FY2010 · CA · contact PI
Novel Clinical Diagnostic Targets For Detection of Invasive Mold Aspergillosis$237,000
R21 · FY2010 · AI
Molecular Targeting of Lymphatic Endothelial Receptors for Ligand-directed Imagin$200,968
R01 · FY2010 · CA · contact PI
Targeted Modulation of Angiogenesis by VEGFR Peptidomimetic Antagonists$406,500
R01 · FY2009 · EY · contact PI
Integration of Vascular Genomics and Proteomics for Diagnosis and Therapy of Canc$340,506
R33 · FY2009 · CA · contact PI
Ligand-Directed Tumor Targeting in Preclinical Models$292,600
R01 · FY2009 · CA · contact PI
Ligand-Directed Targeting in Prostate Cancer Metastasis$247,305
P50 · FY2009 · CA · contact PI
Molecular Targeting of Lymphatic Endothelial Receptors for Ligand-directed Imagin$200,972
R01 · FY2009 · CA · contact PI
Regulatory Roles for Vascular Peptidases in Angiogenesis$355,567
R01 · FY2008 · HL · contact PI
Integration of Vascular Genomics and Proteomics for Diagnosis and Therapy of Canc$337,223
R33 · FY2008 · CA · contact PI
Ligand-Directed Tumor Targeting in Preclinical Models$292,600
R01 · FY2008 · CA · contact PI
Regulatory Roles for Vascular Peptidases in Angiogenesis$355,567
R01 · FY2007 · HL · contact PI
Ligand-Directed Tumor Targeting in Preclinical Models$292,600
R01 · FY2007 · CA · contact PI
Regulatory Roles for Vascular Peptidases in Angiogenesis$366,188
R01 · FY2006 · HL · contact PI
Regulatory Roles for Vascular Peptidases in Angiogenesis$375,000
R01 · FY2005 · HL
Contrasting Properties of Integrin Cytoplasmic Domains$226,500
U01 · FY2004 · CA
TARGETED DELIVERY OF GENES TO ANGIOGENIC VASCULATURE$182,712
R01 · FY2004 · CA
Contrasting Properties of Integrin Cytoplasmic Domains$219,903
U01 · FY2003 · CA
TARGETED DELIVERY OF GENES TO ANGIOGENIC VASCULATURE$177,386
R01 · FY2003 · CA
TARGETING PROSTATE CANCER BONE METASTASIS$291,807
P50 · FY2002 · CA
A RECEPTOR FOR TUMOR HOMING PEPTIDES IN VASCULATURE$274,449
R01 · FY2002 · CA
Contrasting Properties of Integrin Cytoplasmic Domains$213,498
U01 · FY2002 · CA
TARGETED DELIVERY OF GENES TO ANGIOGENIC VASCULATURE$172,223
R01 · FY2002 · CA
CD13 IN TUMOR ANGIOGENESIS$0
P01 · FY2002 · CA
CORE--ENDOTHELIAL CELL CULTURE AND ANGIOGENESIS FACILITY$0
P01 · FY2002 · CA
CORE--ENDOTHELIAL CELL CULTURE AND ANGIOGENESIS FACILITY$0
P01 · FY2002 · CA
CORE--ENDOTHELIAL CELL CULTURE AND ANGIOGENESIS FACILITY$0
P01 · FY2002 · CA
CORE--ENDOTHELIAL CELL CULTURE AND ANGIOGENESIS FACILITY$0
P01 · FY2002 · CA
CD13 IN TUMOR ANGIOGENESIS$0
P01 · FY2002 · CA
CD13 IN TUMOR ANGIOGENESIS$0
P01 · FY2002 · CA
CD13 IN TUMOR ANGIOGENESIS$0
P01 · FY2002 · CA
A RECEPTOR FOR TUMOR HOMING PEPTIDES IN VASCULATURE$266,456
R01 · FY2001 · CA
Contrasting Properties of Integrin Cytoplasmic Domains$207,279
U01 · FY2001 · CA
TARGETED DELIVERY OF GENES TO ANGIOGENIC VASCULATURE$167,205
R01 · FY2001 · CA
CORE--ENDOTHELIAL CELL CULTURE AND ANGIOGENESIS FACILITY$0
P01 · FY2001 · CA
TARGETING PROSTATE CANCER BONE METASTASIS$0
P50 · FY2001 · CA
CD13 IN TUMOR ANGIOGENESIS$0
P01 · FY2001 · CA
A RECEPTOR FOR TUMOR HOMING PEPTIDES IN VASCULATURE$188,433
R01 · FY2000 · CA
TARGETED DELIVERY OF GENES TO ANGIOGENIC VASCULATURE$162,336
R01 · FY2000 · CA
CORE--ENDOTHELIAL CELL CULTURE AND ANGIOGENESIS FACILITY$0
P01 · FY2000 · CA
CD13 IN TUMOR ANGIOGENESIS$0
P01 · FY2000 · CA